What’s the current market cap for FMC stock?

FMC (FMC) has a market cap of $1.4bn as of June 19, 2026.

What is the P/E ratio for FMC stock?

The price to earnings (P/E) ratio for FMC (FMC) stock is 0 as of June 19, 2026.

Does FMC stock pay dividends?

Yes, the FMC (FMC) stock pays dividends to shareholders. As of June 19, 2026, the dividend rate is $1.32 and the yield is 2.77%. FMC has a payout ratio of 0% on a trailing twelve-month basis.

When is the next FMC dividend payment date?

The next FMC (FMC) dividend payment is scheduled for July 16, 2026.

What is the beta indicator for FMC?

FMC (FMC) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy FMC stock | $FMC Share Price

13:30

15:10

16:45

18:25

20:00

About FMC

FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.

Ticker

$FMC

Sector

Materials

Primary listing

NYSE

Employees

5,500

Headquarters

Philadelphia, United States

Website

www.fmc.com

FMC Metrics

BasicAdvanced

$1.4bn

-$20.01

0.37

$1.32

2.77%

What the Analysts think about FMC

Analyst ratings (Buy, Hold, Sell) for FMC stock.

Bulls say / Bears say

FMC’s herbicide active ingredient bixlozone (Isoflex active) received EU regulatory approval in April 2026, the first new herbicide active ingredient approved in the region since 2019, unlocking access to over 55 million hectares of planted EU acreage from 2027 onward. (Reuters)

FMC reported that new active ingredient sales doubled year-over-year in Q1 2026, showing commercial momentum for pipeline molecules including Isoflex, fluindapyr, and Dodhylex. (Reuters)

After a Q1 beat on revenue and adjusted EPS, BMO Capital reiterated its Market Perform rating and $15 price target for FMC, citing the company’s reaffirmed full-year 2026 guidance and progress on debt reduction and asset sales. (Reuters)

FMC’s board has authorized a strategic review to consider options including a possible sale of the company, reflecting management’s efforts to address a weak agricultural economy and rising competition from generics. (Bloomberg)

In December 2025, S&P Global Ratings downgraded FMC to BB+ from investment grade, citing persistently weak credit metrics and uncertainty about the company’s future performance. (Reuters)

Moody’s downgraded FMC to Ba1 in March 2026 due to challenges from the expiration of patents on key products and projected leverage above 5.0x, highlighting increased refinancing and liquidity risks. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 1 Jun 2026.

FMC Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

FMC Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

FMC reported that new active ingredient sales doubled year-over-year in Q1 2026, showing commercial momentum for pipeline molecules including Isoflex, fluindapyr, and Dodhylex. (Reuters)

In December 2025, S&P Global Ratings downgraded FMC to BB+ from investment grade, citing persistently weak credit metrics and uncertainty about the company’s future performance. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 1 Jun 2026.